Tuesday, April 09, 2019 10:06:12 PM
Based on the way this is written (Filing dated Nov.9th,2018 Form 424B5),and depending on what price shares are sold at and what kind of volume is happening,whether there is news or not that the stock is moving on.....all these factors need consideration AND will determine how much dilution,IF any.
I think it is quite possible something good might happen "financially" for the company that could pre-empt any stock sales,whether that is a buyout of 1st Detect,buyout of ASTC entirely,cash infusion done in a more "creative" way? I'm sure there are many who are creating their own "scenarios" and believe they have it "figured out";I seriously doubt it;It wouldn't be a surprise ,or shouldn't be a surprise if the company sells stock into the next good news;The amount of dilution possible under this current "prospectus supplement" is minimal ....especially if the stock price is moving much higher over some long awaited good news for long term or short term shareholders and they can show either a huge influx of cash or the ability to produce revenue on a continuous basis.
Disclosure:I've been in and out of this stock a lot over 10 years and every time I think I have it figured out ,the winds change;My intentions now however have altered a bit and I've developed a possible longer term outlook;I cannot commit to that but I am prepared for it;The problem is there is too much "unknown" and I feel a bit uncomfortable committing to a longer term plan for myself until I know what the future starts looking like.
My timing with ASTC has been lousy over those 10 years because of things like what is occuring right now and my impatience ,(which sometimes is very warranted),selling to early,selling to late and buying timing as well .... trying to time the moves;My current "investing" strategy here is to accumulate as many shares as possible and maintain a core postition,selling a few shares possibly as it rises/the eventual news will determine how far I go before I sell 1 single share,not a set parameter, NOT having sell orders already in prior to any moves.
I would NOT use stops on this stock under any circumstances;It is too illiquid and you will end up losing your shirt in the larger % of cases ,in my opinion;I think you are foolish to use stops on this stock;You have to maintain a mental attitude of not selling until you get some profit at minimum.
To each his own I'm not here to give anyone advice;I'm simply chattering my thoughts and what I think,I'm sure others think different,but that's what makes a market doesn't it?
Lastly,as far as my personal trading habits I am not a "large" shareholder in many circles but not going to disclose how many shares I have because it shouldn't matter;Everyone has their own thresholds of risk,tolerance and fiduciary ability.
REASONS STOCK PRICE IS STILL UNDER $4.00
1.LACK OF NEWS from the company
2.LISTED with ECAC but no sales anouncements yet
3.LACK OF FUNDS and fears of coming dilution (which I think is unfounded based on the prospectus below)
4.NO TSA approval yet;Seems overdue or are we just impatient? (WE DON'T
KNOW THE ANSWER BECAUSE see #1 lack of news)
5.COMPETITION>> SMITHS being #1, who just landed a 95 Million $ contract
6.NEVER a CONFERENCE call
I'm certain others could add more reasons,AND other complaints but I think those are my highlights.
.............
...............
Filing dated Nov.9th,2018 Form 424B5
ASTROTECH CORPORATION
$6,602,390
Common Stock
We have entered into an At Market Issuance Sales Agreement, or sales agreement, with B. Riley FBR, Inc. (the “Distribution Agent”), dated November 9, 2018, relating to the sale of shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, under this prospectus supplement and accompanying prospectus we may offer and sell shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $6,602,390 from time to time through the Distribution Agent, acting as agent.
Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus will be made by any method permitted that is deemed an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act. The Distribution Agent is not required to sell any specific amount, but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.
The Distribution Agent will be entitled to compensation at a commission rate of 3.0% of the gross sales price per share sold. In connection with the sale of the common stock on our behalf, the Distribution Agent will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of the Distribution Agent will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to the Distribution Agent with respect to certain liabilities, including liabilities under the Securities Act.
Our common stock is listed on the Nasdaq Capital Market under the symbol “ASTC.” On November 7, 2018, the last reported sale price of our common stock on the Nasdaq Capital Market was $3.16 per share.
The aggregate market value of our outstanding common stock held by non-affiliates, or public float, is approximately $19,807,170, based on approximately 4,505,019 shares of outstanding common stock, of which approximately 961,697 shares are held by affiliates, and a price of $5.59 per share, which was the closing price of our common stock on the Nasdaq Capital Market on September 21, 2018. We have sold $0 of securities as calculated pursuant to General Instruction I.B.6 of Form S-3 during the prior 12 calendar month period that ends on and includes the date of this prospectus supplement. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in public primary offerings on Form S-3 with a value exceeding more than one-third of our public float in any 12 calendar month period so long as our public float remains below $75.0 million.
https://www.sec.gov/Archives/edgar/data/1001907/000156459018028979/astc-424b5.htm
"Diversification is a protection against ignorance. It makes very little sense for those who know what they're doing."
Recent ASTC News
- Astrotech Announces Listing to the GSA as an Approved United States Government Vendor • GlobeNewswire Inc. • 04/08/2024 01:00:00 PM
- Astrotech to Showcase the Tracer 1000 Trace Detector at ISC West Conference • GlobeNewswire Inc. • 04/02/2024 01:00:00 PM
- Astrotech Introduces the “Gold Standard” of Mass Spectrometry into Narcotics Detection Market with its State-of-the-Art Tracer 1000 • GlobeNewswire Inc. • 03/25/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 09:31:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:37:04 PM
- Astrotech Reports Second Quarter Of Fiscal Year 2024 Financial Results • GlobeNewswire Inc. • 02/12/2024 09:35:27 PM
- IBN Coverage Initiated for Astrotech Corp. • GlobeNewswire Inc. • 01/17/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:28:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 10:29:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 04:13:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:57:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/29/2023 10:54:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/29/2023 10:35:31 PM
- Astrotech Presents the First Process Control System for Cannabinoid Oil Distillation Systems • GlobeNewswire Inc. • 11/28/2023 02:04:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 06:23:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 08:58:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 04:52:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 06:34:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:42:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:37:28 PM
- Astrotech Reports First Quarter of Fiscal Year 2024 Financial Results • GlobeNewswire Inc. • 11/13/2023 09:30:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 02:04:46 PM
- 1ST DETECT SECURES SIGNIFICANT PURCHASE ORDER FOR ADDITIONAL CHECKPOINT SECURITY UNITS • GlobeNewswire Inc. • 11/13/2023 02:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/01/2023 08:43:09 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/01/2023 08:34:28 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM